Agenus Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AGEN Nasdaq 2834 www.agenusbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Agenus Inc.

Agenus (AGEN) Q3 Earnings Meet Estimates - Nov 5th, 2026 5:00 pm
Agenus: Q3 Earnings Snapshot - Nov 5th, 2026 4:39 pm
Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment Milestones - Nov 5th, 2026 2:14 pm
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study - Nov 5th, 2026 5:30 am
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat - Nov 2nd, 2026 4:05 pm
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer - Nov 2nd, 2026 4:42 am
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026 - Oct 25th, 2026 5:00 am
Agenus to Provide Third Quarter 2026 Financial Report and Development Update - Oct 22nd, 2026 2:30 pm
Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial - Oct 20th, 2026 3:02 pm
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference - Oct 9th, 2026 1:23 pm
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer - Oct 8th, 2026 5:30 am
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Oct 3rd, 2026 8:50 am
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 - Oct 2nd, 2026 7:00 am
Agenus (AGEN) Stock Fair Value Rises After Trial Updates And Fresh Financing - Sep 19th, 2026 8:09 pm
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Sep 10th, 2026 5:30 am
Agenus to Participate in Upcoming September Investor Conferences - Aug 31st, 2026 5:30 am
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism - Aug 28th, 2026 8:07 am
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer - Aug 26th, 2026 8:05 am
Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight - Aug 19th, 2026 8:31 am
Agenus (AGEN) Stock Fair Value Falls After Analysts Rework Pipeline And Financing Assumptions - Aug 16th, 2026 7:07 am